Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development

Transplantation

Volumn 100, Issue 11, 2016, Pages 2479-2485

  Rodrigo, Emilio ^a   Segundo, David San ^a   Fernández Fresnedo, Gema ^a   López Hoyos, Marcos ^a   Benito, Adalberto ^a   Ruiz, Juan Carlos ^a   De Cos, Maria Angeles ^a   Arias, Manuel ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DONOR SPECIFIC ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG; ALLOANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; DEATH CENSORED GRAFT LOSS; DIAGNOSTIC TEST ACCURACY STUDY; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; AGED; BIOSYNTHESIS; BLOOD; DONOR; HISTOCOMPATIBILITY TEST; MIDDLE AGED;

ADULT; AGED; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TISSUE DONORS;

EID: 84951334938     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001040     Document Type: Article

References (30)

1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant. 2011;11:450.
2. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9:527.
3. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12:388.
4. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157.
5. Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev (Orlando). 2015;29:78.
6. Shemesh E, Fine RN. Is calculating the standard deviation of tacrolimus blood levels the new gold standard for evaluating non-adherence to medications in transplant recipients? Pediatr Transplant. 2010;14:940.
7. Kahan BD, Welsh M, Urbauer DL, et al. Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs. J Am Soc Nephrol. 2000;11:1122-1131.
8. Borra LC, Roodnat JI, Kal JA, et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010;25:2757.
9. Hsiau M, Fernandez HE, Gjertson D, et al. Monitoring nonadherence and acute rejection with variation inblood immunosuppressant levelsin pediat-ric renal transplantation. Transplantation. 2011;92:918.
10. Sapir-Pichhadze R, Wang Y, Famure O, et al. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int. 2014;85:1404.
11. Heilman RL, Nijim A, Desmarteau YM, et al. De novo donor-specific human leukocyte antigen antibodies early after kidney transplantation. Transplantation. 2014;98:1310.
12. Massey EK, Meys K, Kerner R, et al. Young adult kidney transplant recip-ients: nonadherent and happy. Transplantation. 2015;99:e89-96.
13. Pollock-Barziv SM, Finkelstein Y, Manlhiot C, et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant. 2010;14:968.
14. Kerkar N, Annunziato RA, Foley L, et al. Prospective analysis of non-adherence in autoimmune hepatitis: a common problem. J Pediatr Gastroenterol Nutr. 2006;43:629.
15. Van Gelder T. Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation. Kidney Int. 2014;85:1267-1268.
16. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23:1296-1310.
17. Kuypers DRJ, Peeters PC, Sennesael JJ, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95: 333-340.
18. Wu MJ, Cheng CY, Chen CH, et al. Lower variability of tacrolimus trough concentration after conversion from Prograf to Advagraf in stable kidney transplant recipients. Transplantation. 2011;92:648-652.
19. Stifft F, Stolk LM, Undre N, et al. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. Transplantation. 2014;97:775-780.
20. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplan-tation. 2013;95:410.
21. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol. 2005; 16:2804.
22. El Ters M, Grande JP, Keddis MT, et al. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant. 2013;13:2334.
23. Hirai T, Furusawa M, Omoto K, et al. Analysis of predictive and preventive factors for de novo DSA in kidney transplant recipients. Transplantation. 2014;98:443.
24. Chemouny JM, Suberbielle C, Rabant M, et al. De novo donor-specific human leukocyte antigen antibodies in nonsensitized kidney transplant recipients after T cell-mediated rejection. Transplantation. 2015;99:965.
25. Brokhof MM, Sollinger HW, Hager DR, et al. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation. 2014; 97:612.
26. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant. 2012;12:1192.
27. Kamar N, Del Bello A, Congy-Jolivet N, et al. Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen. Clin Transplant. 2013;27:455.
28. Ruiz San Millán JC, López-Hoyos M, Segundo DS, et al. Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors. Transpl Int. 2014;27:847.
29. ÓLeary J, Samaniego M, Crespo Barrio M, et al. The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients. Trans-plantation. 2016;100:39-53.
30. Süsal C, Wettstein D, Döhler B, et al. Association of kidney graft loss with de novo produced donor-specific and non-donor-specific HLA antibodies detected by single antigen testing. Transplantation. 2015; 99:1976-1980.